Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer

Breast Cancer

Volumn 17, Issue 3, 2010, Pages 205-211

  Manga, Gumersindo Pérez ^a   Shahi, Parham Khosravi ^a   Ureña, Miguel Méndez ^b   Pereira, Rosa Quiben ^b   Plaza, María Isabel Palomero ^a   Peron, Yann Izarzugaza ^a   Val, Ricardo González Del ^a   Carrión, Joaquín Belón ^c   Cañón, Esperanza Pérez ^a   Alfonso, Pilar García ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL DE MÓSTOLES   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Anthracyclines; Capecitabine; Preoperative chemotherapy; Taxanes

Indexed keywords

ANTIEMETIC AGENT; CAPECITABINE; DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HORMONE RECEPTOR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; TAXOID;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; INFLAMMATORY BREAST CANCER; LIVER FUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING; ADJUVANT THERAPY; ADOLESCENT; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PREOPERATIVE CARE; REMISSION; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PREOPERATIVE CARE; REMISSION INDUCTION; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955515628     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-009-0136-6     Document Type: Article

References (24)

1. B Fisher A Brown EP Mamounas S Wieand A Robidoux RG Margolese, et al. 1997 Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B18 J Clin Oncol 15 2483 2493 1:CAS:528:DyaK2sXkslymsr8%3D 9215816
2. M Kaufmann GN Hortobagyi A Goldhirsch S Scholl A Makris P Valagussa, et al. 2006 Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update J Clin Oncol 24 1940 1949 10.1200/JCO.2005.02.6187 16622270 (Pubitemid 46638994)
3. D Mauri N Pavlidis JP Ioannidis 2005 Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis J Natl Cancer Inst 97 188 194 10.1093/jnci/dji021 15687361 (Pubitemid 40277368)
4. V Guarneri K Broglio SW Kau M Cristofanilli AU Buzdar V Valero, et al. 2006 Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 1037 1044 10.1200/JCO.2005.02.6914 16505422 (Pubitemid 46638799)
5. RL Smoot CA Koch AC Degnim S Sterioff JH Donohue CS Grant, et al. 2006 A single-center experience with inflammatory breast cancer, 1985-2003 Arch Surg 141 567 572 10.1001/archsurg.141.6.567 16785357
6. S Han SB Kim SS Kang WC Noh NS Paik ES Chang, et al. 2006 A phase II study of neoadjuvant docetaxel plus doxorubicin (KBCS-01) in stage II, III breast cancer Breast Cancer Res Treat 98 57 61 10.1007/s10549-005-9131-6 1:CAS:528:DC%2BD28XmvVaqsbg%3D 16752226 (Pubitemid 44050780)
7. R Quiben MI Palomero J Cassinello G Pérez-Manga 2001 Doxorubicin combined with weekly docetaxel in locally advanced or inflammatory breast cancer (BC) Goti Study Group Proc Am Soc Clin Oncol 37 1901 (abstr 1901)
8. RM Layman DG Thomas KA Griffith JB Smerage MA Helvie MA Roubidoux, et al. 2007 Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer Clin Cancer Res 13 4092 4097 10.1158/1078-0432.CCR-07-0288 1:CAS:528:DC%2BD2sXnvVCiurg%3D 17634534 (Pubitemid 47105970)
9. N Tagaya A Nakagawa S Mori K Hamada N Suzuki K Kubota 2006 Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer Gan To Kagaku Ryoho 33 39 42 1:CAS:528:DC%2BD28XhtlOlu7k%3D 16410696
10. M Venturini L Del Mastro O Garrone C Angiolini M Merlano M Bergaglio, et al. 2002 Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer Ann Oncol 13 546 552 10.1093/annonc/mdf056 1:STN:280:DC%2BD38zhsVynsw%3D%3D 12056704 (Pubitemid 34461137)
11. I Sachelarie ML Grossbard M Chadha S Feldman M Ghesani RH Blum 2006 Primary systemic therapy of breast cancer Oncologist 11 574 589 10.1634/theoncologist.11-6-574 1:CAS:528:DC%2BD28XhtFGhu7vK 16794237 (Pubitemid 43967613)
12. A Makris TJ Powles SE Ashley J Chang T Hickish VA Tidy, et al. 1998 A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer Ann Oncol 9 1179 1184 10.1023/A:1008400706949 1:STN:280:DyaK1M%2FnvFSnsg%3D%3D 9862047 (Pubitemid 28552806)
13. P Rastogi SJ Anderson HD Bear CE Geyer MS Kahlenberg A Robidoux, et al. 2008 Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J Clin Oncol 26 778 785 10.1200/JCO.2007.15.0235 18258986 (Pubitemid 351264391)
14. L Gianni L Baselga W Eiermann V Guillem Porta V Semiglazov A Lluch, et al. 2005 Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy Clin Cancer Res 11 8715 8721 10.1158/1078-0432.CCR-05-0539 1:CAS:528:DC%2BD2MXhtlWrsbrI 16361558 (Pubitemid 43005921)
15. HD Bear S Anderson RE Smith CE Geyer EP Mamounas B Fisher, et al. 2006 Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27 J Clin Oncol 24 2019 2027 10.1200/JCO.2005.04.1665 1:CAS:528:DC%2BD28Xlt1amur0%3D 16606972 (Pubitemid 46622110)
16. M Colleoni G Viale D Zahrieh G Pruneri O Gentilini P Veronesi, et al. 2004 Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment Clin Cancer Res 10 6622 6628 10.1158/1078-0432.CCR-04-0380 1:CAS:528: DC%2BD2cXot1Oiu7o%3D 15475452 (Pubitemid 39346559)
17. AE Ring IE Smith S Ashley LG Fulford SR Lakhani 2004 Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer Br J Cancer 91 2012 2017 10.1038/sj.bjc.6602235 1:CAS:528:DC%2BD2cXhtVOjsLbL 15558072 (Pubitemid 40128767)
18. G von Minckwitz G Raab A Caputo M Schütte J Hilfrich JU Blohmer, et al. 2005 Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group J Clin Oncol 23 2676 2685 10.1200/JCO.2005.05.078 (Pubitemid 46179457)
19. MC Green AU Buzdar T Smith NK Ibrahim V Valero MF Rosales, et al. 2005 Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks J Clin Oncol 23 5983 5992 10.1200/JCO.2005.06.232 1:CAS:528:DC%2BD2MXhtVKgtb3O 16087943
20. SD Heys AW Hutcheon TK Sarkar 2002 Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial Clin Breast Cancer 3 S69 S74 10.3816/CBC.2002.s.015 12435290
21. P Khosravi G Pérez-Manga 2006 La relevancia clínica de la sobreexpresión de HER-2 en el cáncer de mama An Med Int 23 103 104
22. C Wenzel D Hussian R Bartsch U Pluschnig GJ Locker M Rudas, et al. 2004 Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study J Cancer Res Clin Oncol 30 400 404
23. AU Buzdar NK Ibrahim D Francis DJ Booser ES Thomas RL Theriault, et al. 2005 Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23 3676 3685 10.1200/JCO.2005.07.032 1:CAS:528:DC%2BD2MXlslWntr8%3D 15738535
24. E Rivera JA Mejia BK Arun RB Adinin RS Walters A Brewster, et al. 2008 Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer Cancer 112 1455 1461 10.1002/cncr.23321 1:CAS:528:DC%2BD1cXktlKrtbc%3D 18300256 (Pubitemid 351459423)